PegBio Company
Founded in 2008, Suzhou city-based PegBio is a bio-pharmaceutical company specializing in the development of innovative drugs to combat diabetes and obesity. Its key product PB-119, an agonist of glucagon-like peptide 1 (GLP-1), allows diabetes patients to take medicine once a week, instead of requiring daily injections.
Industry:
P4 Medicine
Headquarters:
Suzhou, Jiangsu, China
Zip:
11-50
Founded Date:
2008-01-01
Employees Number:
11-50
Acquisitions Number:
7
Investors Number:
23102823
Total Funding:
$1M to $10M
Estimated Revenue:
$1M to $10M
Last Funding Date:
Series E
Last Funding Type:
info@pegbio.com
Register and Claim Ownership